Opinion ID: 1034626
Heading Depth: 3
Heading Rank: 1

Heading: An isolated variant of a parent alpha-amylase,

Text: wherein:
to SEQ ID NO: 6 [BSG alpha-amylase], (b) the variant comprises a substitution of serine at position 239 relative to the parent alpha- amylase, using the amino acid sequence of SEQ ID NO: 8 [BLA alpha-amylase] for de- termining position numbering, and (c) the variant has increased thermostability relative to the parent alpha-amylase, wherein 10 NOVOZYMES A/S v. DUPONT NUTRITION BIOSCIENCES thermostability is determined at pH 4.5, 90° C. and 5 ppm calcium and has alpha-amylase activity. ’723 patent col. 87 ll. 40–51 (emphasis added). Like claim 1, all claims of the ’723 patent require an alpha-amylase variant with at least the following three features: (1) a parent sequence having at least 90% homology with BSG alpha-amylase; (2) a substitution at position S239; and (3) increased thermostability at 90°C, pH 4.5, and 5 ppm calcium. Each of those limitations can be found at points within the underlying 2000 application, but, outside of the ’723 patent’s claims, Novozymes never presented them together in any particular embodiment and did not highlight the BSG parent or position 239 among the other disclosed options.